dronabinol has been researched along with Arterial Occlusive Diseases in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bernatskaia, NA; Krylatov, AV; Maslov, LN; Mechoulam, R; Pertwee, RG; Sal'nikova, OM; SharaevskiÄ, MA; Stefano, GB | 1 |
Abramsky, O; Leker, RR; Ovadia, H; Shohami, E | 1 |
2 other study(ies) available for dronabinol and Arterial Occlusive Diseases
Article | Year |
---|---|
[Increase of the heart arrhythmogenic resistance and decrease of the myocardial necrosis zone during activation of cannabinoid receptors].
Topics: Aconitine; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Arterial Occlusive Diseases; Camphanes; Cannabinoids; Coronary Artery Disease; Dronabinol; Epinephrine; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB2; Receptors, Cannabinoid; Receptors, Drug; Rimonabant | 2002 |
Dexanabinol; a novel neuroprotective drug in experimental focal cerebral ischemia.
Topics: Animals; Arterial Occlusive Diseases; Disease Models, Animal; Dronabinol; Drug Evaluation, Preclinical; Excitatory Amino Acid Antagonists; Hypertension; Ischemic Attack, Transient; Male; Neuroprotective Agents; Nitric Oxide Synthase; Rats; Rats, Inbred SHR; Tumor Necrosis Factor-alpha | 1999 |